Rapid Resolution of Atypical Hemolytic Uremic Syndrome by Eculizumab Treatment
Childhood Kidney Diseases
;
: 138-142, 2020.
Artículo
en Inglés
| WPRIM
| ID: wpr-831205
ABSTRACT
Atypical hemolytic uremic syndrome (aHUS) is an extremely rare and life-threatening disorder. Typical HUS is often caused by Shiga toxin-positive Escherichia coli, while aHUS is caused by dysregulation of the alternative pathway of the complement system in association with genetic abnormalities or development of autoantibodies. Eculizumab, a humanized anti-complement 5 monoclonal antibody, is recommended for the treatment of aHUS, but its long-term safety and efficacy in pediatric patients remain under review. In this paper, we report a pediatric case of aHUS with anti-complement factor H autoantibodies, who was treated successfully with eculizumab.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Inglés
Revista:
Childhood Kidney Diseases
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS